Stock listing

H. Lundbeck A/s Class A

Selected listing: HLUNAC · AQUISUK · DKK · GB

H. Lundbeck A/s Class A (Aquis:HLUNAC), Health Technology. Latest release Jun 24, 2025: Lundbeck receives orphan drug designation in the US and EU for Lu…

HLUNAC:AQUISUKDKKGBUpdated October 2, 2026

Ticker: Aquis:HLUNAC
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: Aquis
Currency: DKK

About H. Lundbeck A/s Class A

H. Lundbeck A/s Class A is a public company based in Denmark, focusing on pharmaceuticals, particularly in the field of mental health. Lundbeck is known for its commitment to developing innovative treatments for psychiatric and neurological disorders.

Latest news from H. Lundbeck A/s Class A

Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia

June 24, 2025

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

June 21, 2025

All H. Lundbeck A/s Class A news →

Events

Replays

H Lundbeck A/S B (HLBBF) Q2 2026 Earnings Call
Wed, Aug 19, 2026 · 07:00 AM ET
Watch
H Lundbeck A/S B (HLBBF) Q1 2026 Earnings Call
Wed, May 13, 2026 · 07:00 AM ET
Watch
H Lundbeck A/S B (HLBBF) Q4 2025 Earnings Call
Wed, Feb 04, 2026 · 07:00 AM ET
Watch

Research H. Lundbeck A/s Class A

H. Lundbeck A/s Class A company profile

View the public company page for H. Lundbeck A/s Class A on 6ix.

H. Lundbeck A/s Class A news

Read company news and market updates connected to H. Lundbeck A/s Class A.

H. Lundbeck A/s Class A investor events

Find investor webinars, events, and replay context for H. Lundbeck A/s Class A.